Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Am-Pharma B V has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single prosecution matter is assigned to 1 distinct examiner, DICKENS, AMELIA NICOLE, who is the only official currently evaluating the company's pending claims. The involvement of 1 distinct art unit suggests that the prosecution is confined to a specific technical group within the patent office. This localized activity indicates a highly targeted strategy for the company's current intellectual property development.
The busiest examiner, DICKENS, AMELIA NICOLE, is responsible for 1 pending office action, which constitutes the full extent of the company's current pending activity. This distribution of 1 action to the busiest examiner out of the total pending workload means that the company's success in the Biotechnology & Pharmaceuticals field is currently dependent on a single individual's review. Additionally, the 1 distinct art unit involved provides the sole administrative and technical framework for the company's current interactions with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKENS, AMELIA NICOLE | 1 | 47.2% | +21.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18952680 | RECOMBINANT ALKALINE PHOSPHATASE FOR USE IN TREATING SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY | DICKENS, AMELIA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18952680 | RECOMBINANT ALKALINE PHOSPHATASE FOR USE IN TREATING SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY | DICKENS, AMELIA NICOLE | 1645 | §112 | Non-Final OA | — | Pending | Nov 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAm-Pharma B V has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Amelia Nicole Dickens has the most, with 1 of Am-Pharma B V's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
